|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable (net of allowance for doubtful accounts of $13 in 2026 and $12 in 2025) | ||||||||||||||||||||
| Inventories (excludes inventories of $273 in 2026 and $236 in 2025 classified in Other assets) | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangibles, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Noncurrent assets held for sale | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||||||
| Current portion of long-term debt and short-term borrowings | ||||||||||||||||||||
| Trade accounts payable | ||||||||||||||||||||
| Accrued and other current liabilities | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other noncurrent liabilities | ||||||||||||||||||||
| Noncurrent liabilities held for sale | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Organon & Co. Stockholders’ Equity: | ||||||||||||||||||||
| Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 262,609 in 2026 and 260,316 in 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total Stockholders’ Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Common stock, shares issued | ||||||||||||||||||||
Loading...
